Trial Profile

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neflamapimod (Primary) ; Ioflupane 123I
Indications Lewy body disease
Focus Proof of concept; Therapeutic Use
Acronyms RewinD-LB
Sponsors CervoMed; EIP Pharma

Most Recent Events

22 Apr 2026 Results presented in the CervoMed Inc Media Release.
07 Apr 2026 According to CervoMed Inc. media release, data from this trial presented at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, GA,
06 Apr 2026 Actual primary completion date changed from 4 Oct 2024 to 29 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com